News

The good news keeps coming! Zilbrysq (zilucoplan) has been listed on the Pharmaceutical Benefits Scheme (PBS) for generalised Myasthenia Gravis (gMG) patients who are AChR antibody positive.*

WE NEED YOUR HELP

You can help raise awareness about how heat and hot weather affect people living with myasthenia gravis.

Don’t hesitate one more minute!

Register here for the Myasthenia Alliance Australia (MAA) Integrating Physiotherapy into Your Care Team with Physiotherapist Rodney Wenceslao.

Register here for the Myasthenia Alliance Australia (MAA) Integrating Physiotherapy into Your Care Team with Physiotherapist Rodney Wenceslao.

Generalised Myasthenia Gravis (gMG) patients can now have access to a new targeted therapy Ultomiris, via the Pharmaceutical Benefits Scheme (PBS), broadening our treatment options.*

The MAA shared the important moment when Minister Butler announced that this new treatment has been listed, at the annual Rare Disease Day parliamentary event.

Good news. The MAA are pleased to share content from the Optimal CRE Research Project November 2025 webinar and also an opportunity to be involved in future research offered through this project.

Did you know 300 million people worldwide are living with a rare disease?

The MAA is pleased to share with you that a clinical trial is now open for Australian participation. It will potentially offer an additional treatment pathway for myasthenia gravis patients.